Maynard Um
-
-
-
-
-
-
-
Novo Nordisk stock tumbles 10% as key trial misses goal
-
-
-
-
-
-
-
Oral Wegovy reaches 33% of total prescriptions by May
-
-
-
-
-
-
-
TD Cowen raises global GLP-1 sales forecast to $150B by 2030
-
-
-
-
-
-
-
Novo Nordisk's Wegovy shows 21% weight loss regardless of response speed
-
-
-
-
-
-
-
Novo Nordisk reports Q1 earnings on Wednesday: Analysts flag key focus topics
-
-
-
-
-
-
-
Novo Nordisk gets FDA fast track status for ATTR heart disease drug
-
-
-
-
-
-
-
Novo Nordisk (NVO) PT Lowered to $36 at BMO Capital
-
433,566 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

